Article Test

Home  >  Medical Research Archives  >  Issue 149  > Intravenous Immunoglobulin Suppresses Chemotherapy-Induced Peripheral Neurotoxicity Via Macrophage Modulation in Rats and Mice
Published in the Medical Research Archives
Oct 2022 Issue

Intravenous Immunoglobulin Suppresses Chemotherapy-Induced Peripheral Neurotoxicity Via Macrophage Modulation in Rats and Mice

Published on Oct 31, 2022

DOI 

Abstract

 

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a serious adverse effect that leads to treatment discontinuation by patients receiving anticancer therapy. Treatment discontinuation is a serious and life-threatening problem for patients with cancer; hence, there is a need for drugs that suppress the induction of CIPN by anticancer drugs. Here, using rat and mouse models, we showed that intravenous immunoglobulin (IVIg) can suppress CIPN induced by not only paclitaxel but also by doxorubicin. Furthermore, the suppressive effect of IVIg is eliminated when macrophages are depleted. Here, we proposed two novel independent mechanisms underlying the alleviation of CIPN by IVIg. First, IVIg suppresses CIPN in a macrophage-dependent manner. Second, IVIg combined with anticancer drugs can avoid restrictions on the use of anticancer drugs owing to CIPN induction. However, further research is necessary for the bench-to-bedside translation of these novel applications of IVIg. Our findings lay a strong foundation for research on IVIg therapeutics.

Author info

Jun Tanaka, Masahiko Kajii

Have an article to submit?

Submission Guidelines

Submit a manuscript

Become a member

Call for papers

Have a manuscript to publish in the society's journal?